Navigation Links
Most Off-Label Cancer Drug Use for Palliative Care
Date:10/27/2008

International review finds it's an accepted treatment in adults as well as children

MONDAY, Oct. 27 (HealthDay News) -- Between 1990 and 2002, off-label use of anticancer drugs in adults and children ranged between 6.7 percent and 33.2 percent, and most of that off-label use was for palliative care, say researchers who reviewed published studies from a number of countries.

In off-label use, a drug is used to treat conditions that aren't described on the official labeling created when a drug is approved by a regulatory agency such as the U.S. Food and Drug Administration.

Although off-label use of cancer drugs has been reported for most types of cancer, it's most common among patients with metastatic or advanced cancer who are receiving palliative care, noted study author Dr. Dominique Leveque, of the Hopital Hautepierre in Strasbourg, France.

While these patients aren't generally expected to experience clinical benefit, there are circumstances in which off-label anticancer drugs are accepted as the standard of care, such as the use of high-dose carboplatin in some childhood cancers.

But safety is a concern in off-label use, because there's likely little information about tolerance or side effects associated with this kind of use, Leveque said.

He concluded that more research into the extent of off-label use of anticancer drugs is needed and that accurate and unbiased data is urgently required to help doctors make treatment decisions.

The review was published in the November issue of The Lancet Oncology.

More information

The American Cancer Society has more about off-label drug use.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Oct. 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
2. Abortion drugs off-label use may have led to deaths
3. Off-Label Drug Use Needs Strong Oversight
4. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
5. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Study looks at off-label use of biliary stents
9. Get Screened Video Contest Throws a Spotlight on the Importance of Colorectal-Cancer Screening
10. MicroRNAs make for safer cancer treatments
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: